Access to Excellence: Montana Cancer Consortium CCOP (MCC) has since 1996 provided access to NCI sponsored clinical trials for all 46 medical and radiation oncologists in Montana and Northern Wyoming, serving approximately 1 million people in a rural area of 150,000 square miles. Montana health care quality ranks among the highest in the country, but access to care ranks low due to the vastness of the region and concentration of the medical community in a few widespread cities. MCC membership includes 22 affiliate performance sites. As our physicians work to access the population through outlying clinics hundreds of miles from home, MCC provides access to state-of-the-art cancer treatment and control via cutting-edge research of NCI-sponsored trials. This uniquely rural population including 7 Native American reservations does not have convenient access to large university-based treatment facilities, and without nationally recognized clinical trials, patients would not have access to a high level of cancer care. MCC intends to extend access by expanding the physician roster to include other disciplines. Accrual: MCC is currently affiliated with 4 research bases, SWOG, NSABP, NCCTG, and RTOG as well as CTSU. MCC is actively pursuing a fifth affiliation to increase access to cancer control and prevention trials. MCC ranks high in accrual with the research bases accruing more than 4000 participants to clinical trials. The goal is to increase accrual by 5% annually. Quality: MCC is dedicated to quality data and maintains excellent performance reviews and audits. Centralized data management and quality assurance ensure timely registrations and submissions of data. Human subject protection is achieved by central IRB review. Drug accountability is met by a central pharmacy (Billings) and supervised satellites. The goal of MCC is to maintain and enhance this level of quality through education and increased communication. The uniquely rural population of Montana and Northern Wyoming lacks convenient access to large university-based treatment facilities and without nationally-recognized clinical trials patients would not have access to a high level of cancer care. MCC provides access to state-of-the-art cancer treatment and cancer control through cutting edge research of NCI-sponsored clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA067575-18
Application #
8308656
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-09-18
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
18
Fiscal Year
2012
Total Cost
$412,534
Indirect Cost
Name
Montana Cancer Consortium
Department
Type
DUNS #
802713917
City
Billings
State
MT
Country
United States
Zip Code
59101
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8

Showing the most recent 10 out of 149 publications